8-K: Vireo Growth Q4 Revenue Soars 318% on M&A, Eyes Expansion

Vireo Growth Inc. reported a 317.7% year-over-year GAAP revenue increase to $104.5 million in Q4 2025, driven by recent acquisitions, and announced further M&A plans.

Summary

• GAAP revenue for Q4 2025 increased 317.7% year-over-year to $104.5 million.
• GAAP gross profit rose 348.0% year-over-year to $56.9 million, with gross profit margin expanding to 54.4%.
• Adjusted EBITDA grew 347.0% year-over-year to $29.5 million, achieving an Adjusted EBITDA Margin of 28.2%.
• Pro forma same store sales, excluding Minnesota, increased 11.3% year-over-year, and wholesale revenue increased 55% year-over-year.
• The company closed Q4 2025 with $122.5 million in cash.
• Announced pending acquisitions of PharmaCann retail assets in Colorado (estimated $49 million in shares), Eaze Inc. (estimated $47 million in shares plus earnout), and a nonbinding MOU for The Hawthorne Gardening Company LLC, all expected to close in the first half of 2026.
• Completed integration of Deep Roots, Proper, and Wholesome acquisitions, realizing corporate overhead synergies.
• Reported a net loss of $(20.4) million for Q4 2025 and $(68.1) million for the full year 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to robust revenue and EBITDA growth driven by strategic acquisitions, strong cash position, and clear plans for further expansion, despite an increase in net loss which is common during aggressive growth phases.

Positives

• Significant GAAP revenue growth of 317.7% year-over-year to $104.5 million in Q4 2025.
• Strong GAAP gross profit growth of 348.0% year-over-year to $56.9 million, with margin expansion of 380 basis points to 54.4%.
• Adjusted EBITDA increased 347.0% year-over-year to $29.5 million, with margin improvement of 180 basis points to 28.2%.
• Pro forma same store sales, excluding Minnesota, grew 11.3% year-over-year.
• Wholesale revenue increased 55% year-over-year on a pro forma basis.
• Robust cash position of $122.5 million at the end of Q4 2025.
• Successful integration of recent acquisitions (Deep Roots, Proper, Wholesome) leading to corporate overhead synergies.
• Strategic expansion through pending acquisitions of PharmaCann and Eaze, and a potential acquisition of Hawthorne.

Negatives

• Reported a net loss of $(20,372,228) for Q4 2025, compared to a net loss of $(15,701,281) in Q4 2024.
• Full year 2025 net loss increased to $(68,113,908) from $(28,007,509) in 2024.
• Net loss per share for Q4 2025 was $(0.02), and for the full year 2025 was $(0.09).
• New York retail revenue decreased by 29% year-over-year on a pro forma basis.
• Maryland wholesale revenue decreased by 13% year-over-year on a pro forma basis.
• Nevada wholesale revenue decreased by 85% year-over-year on a pro forma basis.
• Significant increase in total current liabilities to $191.5 million from $135.5 million year-over-year.
• Substantial increase in long-term debt, net, to $127.6 million from $61.4 million year-over-year.
• Increase in uncertain tax liability to $119.9 million from $33.3 million year-over-year.

Risks

• The Memorandum of Understanding (MOU) with ScottsMiracle-Gro for the potential acquisition of Hawthorne is non-binding, and there is no assurance a definitive agreement will be reached.
• Uncertainty regarding management's ability to negotiate a definitive agreement with ScottsMiracle-Gro on acceptable terms or at all.
• The company faces risks related to obtaining necessary regulatory and third-party approvals for the completion of its pending and proposed transactions (PharmaCann, Eaze, Schwazze, Hawthorne).
• Potential difficulties in maintaining relationships with suppliers, customers, employees, and other third parties as a result of the pending and proposed transactions.
• The effects of the pending and proposed transactions on the company and the interests of various constituents are uncertain.
• Risks associated with the nature, cost, impact, and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions.
• Risks related to the timing and content of adult-use legislation in markets where the company currently operates.
• Exposure to current and future market conditions, including fluctuations in the market price of the company's subordinate voting shares.
• Risks related to epidemics and pandemics.
• The company's operations are subject to federal, state, local, and foreign government laws, rules, and regulations, including those relating to cannabis operations in the United States, and any changes to such laws or regulations could have an adverse impact.
• Operational, regulatory, and other risks, including those related to the execution of business strategy and management of growth.
• Difficulties inherent in forecasting future events.
• Potential conflicts of interest.
• Risks inherent in an agricultural business and a manufacturing business.
• Concerns regarding liquidity and the company's ability to raise additional financing to continue as a going concern.
• Challenges in meeting the demand for flower in its various markets.
• Uncertainty regarding the company's ability to dispose of its assets held for sale at an acceptable price or at all.

Future Outlook

Vireo Growth Inc. expects to remain acquisitive, continuing to optimize all areas of its business while pursuing further acquisition-related growth opportunities. The pending acquisitions of PharmaCann retail assets, Eaze Inc., and the potential acquisition of The Hawthorne Gardening Company LLC are all anticipated to close in the first half of 2026.

Management Comments

• "Fourth quarter performance remained in line with our expectations and reflected pro forma same store sales growth excluding Minnesota of 11.3% and wholesale growth of 55% over the prior year quarter."
• "As we begin the new year, we will continue optimizing all areas of our business while remaining opportunistic with respect to further acquisition related growth opportunities."

Industry Context

StockSavvy.ai notes that Vireo Growth Inc.'s aggressive M&A strategy, evidenced by the significant revenue growth from recent acquisitions and the announcement of further pending deals, positions it as a consolidator in the fragmented U.S. cannabis market. This approach aligns with a broader industry trend where larger multi-state operators (MSOs) are leveraging capital to expand their footprint and achieve economies of scale amidst varying state-level regulations and the slow pace of federal reform.

Comparison to Industry Standards

• Vireo's Q4 2025 GAAP revenue growth of 317.7% year-over-year significantly outpaces the average organic growth rates seen in the mature segments of the cannabis industry, though this is heavily influenced by M&A.
• The pro forma same-store sales growth of 11.3% (excluding Minnesota) is competitive, comparing favorably to single-digit growth often reported by established MSOs like Curaleaf Holdings, Inc. or Green Thumb Industries Inc. in more mature markets.
• The Adjusted EBITDA margin of 28.2% demonstrates strong operational efficiency, placing Vireo among the more profitable MSOs, often comparable to industry leaders who typically report margins in the 25-35% range.
• The company's strategy of acquiring Eaze, a prominent cannabis delivery platform, and potentially Hawthorne, a major hydroponics supplier, indicates a move towards vertical integration and diversification beyond traditional retail and cultivation, a strategy also pursued by companies like Trulieve Cannabis Corp. to control supply chains and enhance customer reach.

Stakeholder Impact

• Shareholders: Potential for increased value through strategic growth and market expansion, but also dilution from share-based acquisition consideration and increased net losses.
• Employees: Integration of acquired companies suggests potential for streamlined operations and synergies, which could impact roles, but also growth opportunities within a larger entity.
• Customers: Expansion through acquisitions (PharmaCann, Eaze) suggests broader product availability and enhanced delivery services.
• Suppliers: Potential for new or consolidated supplier relationships due to M&A activities.
• Creditors: Increased long-term debt and current liabilities indicate higher leverage, which could be a concern if growth does not materialize as expected.

Next Steps

• Continue optimizing all areas of the business.
• Remain opportunistic with respect to further acquisition-related growth opportunities.
• Close pending acquisitions of PharmaCann retail assets, Eaze Inc., and the potential acquisition of The Hawthorne Gardening Company LLC in the first half of 2026.
• Host a conference call with research analysts on March 17, 2026, at 8:00 a.m. ET to discuss financial results.
• Additional information relating to Q4 2025 results will be available on EDGAR and SEDAR+ later today (March 17, 2026).

Key Dates

Recommendation

Vireo Growth Inc. demonstrates aggressive growth through strategic acquisitions, leading to impressive revenue and EBITDA increases. The strong cash position and clear M&A pipeline are positive indicators for future expansion. However, the substantial net losses and increased leverage, coupled with the inherent risks of integrating multiple large acquisitions and the non-binding nature of the Hawthorne MOU, suggest a 'hold' recommendation. Investors should monitor the successful execution of these integrations and the path to profitability before considering a stronger position.

Keywords

Cannabis, Marijuana, Multi-State Operator, MSO, Acquisition, Merger, Eaze, PharmaCann, Hawthorne Gardening Company, Financial Results, Q4 2025, Revenue Growth, EBITDA, Cannabis Retail, Wholesale Cannabis, Vireo Growth